Please login to the form below

Not currently logged in
Email:
Password:

Akari Therapeutics strengthens board

Hires Michael Grissinger and Dr Peter Feldschreiber

Mike GrissingerBiopharmaceutical company Akari Therapeutics has bolstered its board of directors with the addition of Michael Grissinger and Dr Peter Feldschreiber.

Grissinger (pictured right) has spent 22 years at Johnson & Johnson, holding positions of vice president and head of worldwide pharmaceutical licencing, as well as vice president and head of worldwide pharmaceutical corporate development and M&A.

His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and strategic planning to Akari.

Alongside Grissinger, Dr Peter Feldschreiber also joins the board bringing 20 years’ experience in the pharmaceutical industry.

He has held appointments as senior medical assessor and special litigation coordinator to the healthcare products regulatory agency.

Ray Prudo, executive chairman of Akari Therapeutics, said: “We are pleased to strengthen our board with two individuals that bring such a range and depth of healthcare industry experience.

“As Akari continues its mission to develop and commercialise treatments for orphan autoimmune and inflammatory disease, we look forward to benefitting from Michael’s expertise as a successful business and corporate development leader and Peter’s insight as a medical doctor with experience both in the pharmaceutical industry and the legal and regulatory aspects of healthcare.”

31st January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics